NASDAQ:ALKS
Alkermes plc Stock News
$23.40
+0.190 (+0.82%)
At Close: May 31, 2024
Alkermes' (ALKS) Q1 Earnings Rise Y/Y, Revenues Beat Estimates
12:02pm, Thursday, 29'th Apr 2021
Alkermes' (ALKS) earnings rise year over year in the first quarter of 2021. Revenues surpass estimates.
Alkermes Plc (ALKS) CEO Richard Pops on Q1 2021 Results - Earnings Call Transcript
02:25pm, Wednesday, 28'th Apr 2021
Alkermes Plc (ALKS) CEO Richard Pops on Q1 2021 Results - Earnings Call Transcript
Alkermes (ALKS) Q1 Earnings and Revenues Beat Estimates
09:17am, Wednesday, 28'th Apr 2021
Alkermes (ALKS) delivered earnings and revenue surprises of 320.00% and 10.28%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Alkermes: Q1 Earnings Insights
07:41am, Wednesday, 28'th Apr 2021
Shares of Alkermes (NASDAQ:ALKS) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 1000.00% year over year to $0.11, which beat the estimate of ($0.0
Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting
07:05am, Wednesday, 28'th Apr 2021
DUBLIN, April 28, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the acceptance of two abstracts related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational engi
Alkermes Launches New Disease State Website to Offer Education About Alcohol Dependence
04:01pm, Tuesday, 27'th Apr 2021
DUBLIN, April 27, 2021 /PRNewswire/ -- Myrelationshipwithalcohol.com, a new website sponsored by Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), goes live today to offer education about
Alkermes Initiates ARTISTRY-6 Trial of Nemvaleukin Alfa Monotherapy in Patients With Melanoma
07:00am, Tuesday, 27'th Apr 2021
DUBLIN, April 27, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-6, a global phase 2 trial evaluating the anti-tumor activity, safety and tolerability of
Alkermes to Host Conference Call to Discuss First Quarter 2021 Financial Results
04:00pm, Wednesday, 21'st Apr 2021
DUBLIN, April 21, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.
Alkermes (ALKS) Inks Deal With Merck for Ovarian Cancer Study
09:51am, Thursday, 08'th Apr 2021
Alkermes (ALKS) signs a clinical trial collaboration and supply agreement with Merck to evaluate nemvaleukin alfa in combination with Keytruda for treating platinum-resistant ovarian cancer.
DUBLIN, April 7, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has entered into a clinical trial collaboration and supply agreement with MSD (a tradename of Merck & Co., I
Alkermes to Take Part in Stifel's 3rd Annual CNS Day
04:00pm, Thursday, 25'th Mar 2021
DUBLIN, March 25, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at Stifel's 3rd Annual CNS Day on Thursday, Apr. 1, 202
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
07:00am, Thursday, 11'th Mar 2021
DUBLIN, March 11, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa ("nemvaleukin", formerly referred to as ALKS 4230), the company's investigational engineered
Alkermes' (ALKS) Q4 Earnings and Revenues Beat Estimates
06:10pm, Friday, 12'th Feb 2021
Alkermes (ALKS) beats both earnings and sales estimates in the fourth quarter of 2020.
Alkermes plc (ALKS) CEO Richard Pops on Q4 2020 Results - Earnings Call Transcript
12:53pm, Thursday, 11'th Feb 2021
Alkermes plc (ALKS) CEO Richard Pops on Q4 2020 Results - Earnings Call Transcript
Alkermes (ALKS) Beats Q4 Earnings and Revenue Estimates
09:50am, Thursday, 11'th Feb 2021
Alkermes (ALKS) delivered earnings and revenue surprises of 42.86% and 4.28%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
